Sixty previously untreated patients with high grade non-Hodgkimns lymphomas stages II-IV received cyclophosphamide 750mgm2 i.v., doxorubicin 50mgm2 i.v., and vincristine 2mg i.v. on day 1, prednisolone 100mg p.o. on days 1-5 and etoposide lOOmgm2 i.v. on days 3-5 (CHOP-VP16). After four courses an involved field irradiation with a total dose of 25 Gy was employed and followed by two additional courses of CHOP-VP16. The overall response rate was 93%. with 49 patients (82%) achieving a complete remission (CR). Seven patients had a partial response and four patients showed no response. During a median follow-up period of 55 months, 22 of the 49 patients with CR relapsed, seven of them achieving a second complete remission with the same drug regimen. A maintained complete remission of up to 68 months was seen in 55% of all patients initially achieving CR. The median survival is 43 months. Mean side-effects of this drug regimen were alopecia (89%), nausea/vomiting (76%) and leukopenia (61%). No therapy-related deaths were seen. The results of this study demonstrate that this combined modality treatment produces high complete remission rates and that more than half of these patients achieve long-term disease-free survival.
One of the major objectives of most current therapeutic trials in high grade non-Hodgkin's lymphomas (NHL) is to devise a form of treatment that will consistently induce a high frequency of complete remissions and ultimately benefit more patients in terms of longer disease-free survival. With CHOP, the standard protocol of the past decade introduced by McKelvey et al. (1976) , complete remissions can be obtained in 50-60% of all patients with high grade NHL. Approximately half of these patients will eventually relapse with a poor prognosis. Recent results of studies applying a response-adapted chemotherapy (Fisher et al., 1984) or an intensive chemotherapy with an alternating regimen (Brittinger et al., 1986; Cabamilas et al., 1983; Canellos et al., 1981; Hoppe, 1985; Laurence et al., 1982; Todd et al., 1986) have shown higher complete remission rates which seem to be more stable. Due to the complexity of these protocols they have not been used extensively. In 1982 we initiated a multicentre phase II trial with an easily applicable protocol using the initial CHOP plus VP16 which has been shown to be an effective single agent in NHL (Aisner et al., 1982; Jones et al., 1972 (Peto et al., 1977) .
Results
Between (Figures 2 and 3) . The presence of extranodal involvement (Table II) (Lennert et al., 1978 ; non-Hodgkin's Lymphoma Pathologic Classification Project, 1982) . Klimo et al. (1985) and Coiffier et al. (1986) reached a plateau of overall survival at 76% and 45% of the total patient group respectively. A major disadvantage of these regimens is high toxicity and complexity of the treatment.
Another approach towards intensifying therapy has been the combination of chemotherapy and radiotherapy (Hoppe, 1985; Klimo et al., 1985) . O'Connell et al. (1986) (1986) shows comparable results for the high grade ML (CR rate 84% and a probability of overall survival of 46% at plateau phase).
Toxicity of our protocol was mild and treatment-limiting in courses 5 and 6 only. No therapy-related deaths occurred. Of the 22 patients in CR who relapsed nine did so within previously irradiated areas only, suggesting that the dosage of 25 Gy may not be suflicient and needs to be adjusted. We conclude that this treatment protocol is an easily applicable, safe and highly effective approach for patients with high grade NHL.
